Business Wire

MA-ADVENT-TECHNOLOGIES

Share
Advent Technologies' Chairman and CEO, Dr. Vasilis Gregoriou Elected as Chair of EU IPCEI Hy2Tech Group

Advent Technologies Holdings, Inc. (NASDAQ: ADN), an innovation-driven leader in the fuel cell and hydrogen technology sectors, is pleased to announce the election of its Chairman and CEO, Dr. Vasilis Gregoriou, as the Chair of the Important Project of Common European Interest (“IPCEI”) Hy2Tech Facilitation Group (the “Facilitation Group”). The election took place at the 1st General Assembly for Hy2Tech and Hy2Use, two of the European Union's IPCEIs, which aim to promote research, innovation, and the first industrial deployment of hydrogen technology infrastructure in Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230329005582/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Dr. Vasilis Gregoriou (Chairman and CEO, Advent Technologies) during the 1st General Assembly for Hy2Tech and Hy2Use in Berlin, Germany. (Photo: Business Wire)

The General Assembly was held on March 28, 2023 in Berlin, and was jointly organized by the German Federal Ministry for Economic Affairs and Climate Action and the Ministry of Economic Affairs and Climate Policy of the Netherlands. The General Assembly was attended by executives from companies with projects ratified by the European Union under the IPCEI framework, as well as government and EU officials. Richard Schauperl, Senior Project Manager, R&D Hydrogen and Fuel Cell at AVL GmbH, was also elected as the Deputy Chair of the Facilitation Group.

Advent’s Green HiPo is one of 41 projects ratified under IPCEI Hy2Tech, jointly prepared and notified by fifteen Member States. The Member States have committed up to €5.4 billion in public funding, which is expected to unlock €8.8 billion in private investments. Advent is one of only eight small and medium-sized enterprises (“SMEs”) to have received ratification for its project. Direct participants will collaborate closely with each other and over 300 external partners, such as universities, research organizations, and SMEs across Europe.

Advent's Green HiPo project received a notification in June 2022 of up to €782.1 million in funding from the Greek State, the highest amount of funding received for a project under IPCEI Hy2Tech. The European Union officially ratified the project in July 2022. Green HiPo involves the state of the art development and design of High-Temperature Proton Exchange Membrane ("HT-PEM") fuel cells and electrolyser systems for the production of power and green hydrogen respectively. Green HiPo will be based in the Western Macedonia region of Greece, where a state of the art facility will be established for the R&D and production of innovative fuel cells and electrolyser systems.

Dr. Vasilis Gregoriou, Advent's Chairman and CEO, commented, "I am deeply honored to have been elected as the Chair of the Facilitation Group for IPCEI Hy2Tech, and I am grateful for the trust and support from my fellow industry leaders. Throughout my career, I have been dedicated to driving innovation and collaboration in the technology industry through numerous research and development initiatives. With my knowledge and experience, I am excited to contribute to the achievement of IPCEI Hy2Tech's objectives and ensure that all stakeholders are engaged positively throughout the process. On behalf of the General Assembly, we are all committed to driving Europe's hydrogen industry forward by bringing our innovative projects to life and contributing to the EU's REPowerEU plan."

About Advent Technologies Holdings, Inc.

Advent Technologies Holdings, Inc. is a U.S. corporation that develops, manufactures, and assembles complete fuel cell systems as well as supplying customers with critical components for fuel cells in the renewable energy sector. Advent is headquartered in Boston, Massachusetts, with offices in California, Greece, Denmark, Germany, and the Philippines. With more than 150 patents issued, pending, and/or licensed for fuel cell technology, Advent holds the IP for next-generation HT-PEM that enables various fuels to function at high temperatures and under extreme conditions, suitable for the automotive, aviation, defense, oil and gas, marine, and power generation sectors. For more information, visit www.advent.energy.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company’s ability to maintain the listing of the Company’s common stock on Nasdaq; future financial performance; public securities’ potential liquidity and trading; impact from the outcome of any known and unknown litigation; ability to forecast and maintain an adequate rate of revenue growth and appropriately plan its expenses; expectations regarding future expenditures; future mix of revenue and effect on gross margins; attraction and retention of qualified directors, officers, employees and key personnel; ability to compete effectively in a competitive industry; ability to protect and enhance Advent’s corporate reputation and brand; expectations concerning its relationships and actions with technology partners and other third parties; impact from future regulatory, judicial and legislative changes to the industry; ability to locate and acquire complementary technologies or services and integrate those into the Company’s business; future arrangements with, or investments in, other entities or associations; and intense competition and competitive pressure from other companies worldwide in the industries in which the Company will operate; and the risks identified under the heading “Risk Factors” in Advent’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 31, 2022, as well as the other information filed with the SEC. Investors are cautioned not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read Advent’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements. Advent’s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005582/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HistoSonics Expands Insurance Coverage for Non-Invasive Liver Tumor Treatment to 45.4 Million Elevance Health Members22.10.2025 14:00:00 CEST | Press release

Coverage effective across Elevance Health’s commercial, Medicare, and Medicaid plans in 14 states Decision informed by growing clinical evidence, with additional real-world and long-term safety and efficacy data now being collected across global centers HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced that Elevance Health (formerly Anthem, Inc.) has issued a positive medical policy for the use of histotripsy in the treatment of liver tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022130560/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics The policy, effective October 21, 2025, expands insurance coverage across Elevance Health’s commercial, Medicare, and Medicaid plans in 14 states, including California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virgin

Regula Launches Knowledge Hub to Advance Understanding of Digital ID22.10.2025 14:00:00 CEST | Press release

Regula, a leading developer of identity verification (IDV) solutions and forensic devices, has unveiled a new online resource center, The Road to Digital ID. This knowledge hub is designed to provide a clear, structured guide to what digital identity is, how it’s verified, what risks it brings, and what opportunities it creates. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022763979/en/ Regula’s knowledge hub, The Road to Digital ID, comprises educational content, research findings, tech know-how, and general-interest articles. Across the world, governments and businesses are increasingly embracing digital identity frameworks. In the UK, for example, the government recently announced a new digital ID scheme that will be mandatory for Right to Work checks. While hailed as a modernization effort, it has also reawakened debates about privacy, trust, and governance. Digital ID nailed down Although nearly half of organizatio

AI and Data Leaders NVIDIA, AMD, Snowflake, and Databricks Invest in Uniphore’s Series F to Accelerate Its Leadership in Business AI22.10.2025 13:30:00 CEST | Press release

Uniphore, the Business AI company, today announced the close of its $260 million Series F round. NVIDIA, AMD, Snowflake, and Databricks invested in the round and were joined by financial and sovereign investors including NEA, March Capital, BNF Capital, National Grid Partners, and Prosperity7 Ventures. The new capital will accelerate innovation on its AI and data platform – Business AI Cloud – while deepening its ecosystem. “Our Series F raise marks an exciting milestone for Uniphore. It is unlike most fundraises because, in addition to top-tier financial investors, we are joined by the world’s top AI and data companies,” said Umesh Sachdev, Co-founder and CEO, Uniphore. “This unique combination of capital and strategic alignment validates Uniphore’s position as the Business AI leader. We are seeing exponential adoption from Fortune 500 and other large companies, and this investment allows us to deliver even greater impact and accelerate innovation on behalf of our customers worldwide.

BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 622.10.2025 12:01:00 CEST | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2025 financial results on Thursday, November 6, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting developme

Diligent and Persefoni Form Strategic Partnership to Support Clients in Navigating Sustainability Reporting With Confidence22.10.2025 12:00:00 CEST | Press release

Diligent, the AI leader in governance, risk and compliance SaaS solutions, and Persefoni AI, Inc., a leading Sustainability Management SaaS and AI platform for companies and financial institutions, today announced a strategic partnership to lead the way in sustainability by ensuring clients have the best tools and support to meet their strategic goals and navigate an increasingly complex sustainability landscape with confidence. As part of the agreement, Diligent will transition its carbon accounting clients to Persefoni’s market-leading platform and take an equity position in Persefoni, reinforcing a long-term commitment to innovation in ESG. This partnership ensures Diligent clients benefit from best-in-class capabilities in carbon footprint management, including advanced Scope 3 supply chain sustainability solutions and AI-powered disclosure readiness. "Diligent is committed to providing our customers with the best solutions available to meet today’s needs while preparing for tomorr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye